GENFIT: Half-Year Report of Liquidity Contract with Credit Industriel et Commercial

Lille, France; Cambridge, MA - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced the half-year report of the liquidity contract with Credit Industriel et Commercial.

Under the liquidity contract GENFIT has with Credit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2021:

105,050 shares

EUR646 510.51

During the first half of 2021, total trading was:

On the buy side: 1,013,138 shares for a total amount of EUR4,450,737.46

On the sell side: 997,017 shares for a total amount of EUR4,409,259.22 During this same period, the number of trades were:

On the buy side: 1,926

On the sell side: 1,901

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

27, 911 shares * EUR769 849,43 ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority. As part of GENFIT's comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. In January 2019, GENFIT signed a licensing agreement with Labcorp to make NIS4 technology available for use in clinical research through their drug development subsidiary, Covance. In September 2020, GENFIT signed another licensing agreement with Labcorp to commercialize NIS4 in the US and Canada as a Laboratory Developed Test. Since April 2021, Labcorp has commercialized NASHnext, powered by NIS4, for use in the clinic. GENFIT also continues to explore opportunities to obtain formal marketing authorization of an in vitro diagnostic (IVD) test supported by NIS4 technology. For more information, please visit: https://nis4.com. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext's regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com

Contact:

GENFIT

Investors

Tel: [phone]

E: [e-mail]

PRESS

Media

Stephanie BOYER

Press relations

Tel: [phone]

E: [e-mail]

(C) 2021 Electronic News Publishing, source ENP Newswire